Innovus Pharma (INNV): Targeting $3+ Billion Markets with 13 Commercial Products
Uptick Network – Interview with CEO Fred Ors with ImmunoVaccine Inc.
Kenneth Manzo, CEO Manzo Pharmaceuticals, Visited the Probiotic Manufacturing Plant and was Impressed with the Manufacturer, and Production has Commenced
Uptick Network – Interview with CEO John Lai with PetVivo Holdings, Inc.
Innovus Pharma Is Pleased to Sponsor the San Diego Union Tribune Successful Aging Expo
Premier Biomedical/UTEP Demonstrate New Anti-Cancer Immunotherapy Drug; May Compete Against Best of Big Pharma Drugs
SeeThruEquity Issues Update Note on Innovus Pharmaceuticals, Inc. with a Target Price of $0.80
Premier Biomedical, Inc. Cancer Immunotherapy Research Highlights to be Presented at AACR Conference
Innovus Pharma CEO Provides Shareholder Update
CEO Letter, April, 2016
Manzo Pharmaceuticals Solidifies Deal with USA Based Manufacturers to Begin Producing the Company's Lactose Intolerance Probiotic, Lacto-Freedom
Innovus Pharma CEO Interviewed on CEOLIVE.Tv
Innovus Pharma Announces the Availability of Androferti® in the U.S.
Premier Biomedical, Inc. Engages Agent to Identify Suitable Joint Venture Partners in China and Europe
Innovus Pharmaceuticals Announces the Filing of the Product License to Commercialize Androferti® with Health Canada